カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の組換え活性化凝固第VII因子市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Recombinant Activated Coagulation Factor VII Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19594）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19594
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：77
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の組換え活性化凝固第VII因子市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

組換え活性化凝固第VII因子市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の組換え活性化凝固第VII因子の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

組換え活性化凝固第VII因子市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・バイアル、プレフィルドシリンジ

用途別セグメントは次のように区分されます。
・血友病A、血友病B、その他

世界の組換え活性化凝固第VII因子市場の主要な市場プレーヤーは以下のとおりです。
・Novo Nordisk、LFB SA HEMA Biologics、AryoGen Pharmed

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、組換え活性化凝固第VII因子製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な組換え活性化凝固第VII因子メーカーの企業概要、2019年～2022年までの組換え活性化凝固第VII因子の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な組換え活性化凝固第VII因子メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別組換え活性化凝固第VII因子の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの組換え活性化凝固第VII因子の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での組換え活性化凝固第VII因子市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および組換え活性化凝固第VII因子の産業チェーンを掲載しています。
・第13、14、15章では、組換え活性化凝固第VII因子の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 組換え活性化凝固第VII因子の概要
- 種類別分析（2017年vs2021年vs2028年）：バイアル、プレフィルドシリンジ
- 用途別分析（2017年vs2021年vs2028年）：血友病A、血友病B、その他
- 世界の組換え活性化凝固第VII因子市場規模・予測
- 世界の組換え活性化凝固第VII因子生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Novo Nordisk、LFB SA HEMA Biologics、AryoGen Pharmed
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：バイアル、プレフィルドシリンジ
・用途別分析2017年-2028年：血友病A、血友病B、その他
・組換え活性化凝固第VII因子の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・組換え活性化凝固第VII因子のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・組換え活性化凝固第VII因子のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・組換え活性化凝固第VII因子の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・組換え活性化凝固第VII因子の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Recombinant Activated Coagulation Factor VII market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Recombinant Activated Coagulation Factor VII market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hemophilia A accounting for % of the Recombinant Activated Coagulation Factor VII global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Vial segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant Activated Coagulation Factor VII include Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant Activated Coagulation Factor VII market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Vial
Prefilled Syringe
Market segment by Application can be divided into
Hemophilia A
Hemophilia B
Other
The key market players for global Recombinant Activated Coagulation Factor VII market are listed below:
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Activated Coagulation Factor VII product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Activated Coagulation Factor VII, with price, sales, revenue and global market share of Recombinant Activated Coagulation Factor VII from 2019 to 2022.
Chapter 3, the Recombinant Activated Coagulation Factor VII competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Activated Coagulation Factor VII breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Activated Coagulation Factor VII market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Activated Coagulation Factor VII.
Chapter 13, 14, and 15, to describe Recombinant Activated Coagulation Factor VII sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Recombinant Activated Coagulation Factor VII Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Activated Coagulation Factor VII Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Vial
1.2.3 Prefilled Syringe
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Activated Coagulation Factor VII Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Other
1.4 Global Recombinant Activated Coagulation Factor VII Market Size & Forecast
1.4.1 Global Recombinant Activated Coagulation Factor VII Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant Activated Coagulation Factor VII Sales in Volume (2017-2028)
1.4.3 Global Recombinant Activated Coagulation Factor VII Price (2017-2028)
1.5 Global Recombinant Activated Coagulation Factor VII Production Capacity Analysis
1.5.1 Global Recombinant Activated Coagulation Factor VII Total Production Capacity (2017-2028)
1.5.2 Global Recombinant Activated Coagulation Factor VII Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Activated Coagulation Factor VII Market Drivers
1.6.2 Recombinant Activated Coagulation Factor VII Market Restraints
1.6.3 Recombinant Activated Coagulation Factor VII Trends Analysis
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Recombinant Activated Coagulation Factor VII Product and Services
2.1.4 Novo Nordisk Recombinant Activated Coagulation Factor VII Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 LFB SA HEMA Biologics
2.2.1 LFB SA HEMA Biologics Details
2.2.2 LFB SA HEMA Biologics Major Business
2.2.3 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Product and Services
2.2.4 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 AryoGen Pharmed
2.3.1 AryoGen Pharmed Details
2.3.2 AryoGen Pharmed Major Business
2.3.3 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Product and Services
2.3.4 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant Activated Coagulation Factor VII Breakdown Data by Manufacturer
3.1 Global Recombinant Activated Coagulation Factor VII Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant Activated Coagulation Factor VII Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant Activated Coagulation Factor VII
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Activated Coagulation Factor VII Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant Activated Coagulation Factor VII Manufacturer Market Share in 2021
3.5 Global Recombinant Activated Coagulation Factor VII Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant Activated Coagulation Factor VII Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Activated Coagulation Factor VII Market Size by Region
4.1.1 Global Recombinant Activated Coagulation Factor VII Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant Activated Coagulation Factor VII Revenue by Region (2017-2028)
4.2 North America Recombinant Activated Coagulation Factor VII Revenue (2017-2028)
4.3 Europe Recombinant Activated Coagulation Factor VII Revenue (2017-2028)
4.4 Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue (2017-2028)
4.5 South America Recombinant Activated Coagulation Factor VII Revenue (2017-2028)
4.6 Middle East and Africa Recombinant Activated Coagulation Factor VII Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant Activated Coagulation Factor VII Sales in Volume by Type (2017-2028)
5.2 Global Recombinant Activated Coagulation Factor VII Revenue by Type (2017-2028)
5.3 Global Recombinant Activated Coagulation Factor VII Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant Activated Coagulation Factor VII Sales in Volume by Application (2017-2028)
6.2 Global Recombinant Activated Coagulation Factor VII Revenue by Application (2017-2028)
6.3 Global Recombinant Activated Coagulation Factor VII Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Activated Coagulation Factor VII Sales by Type (2017-2028)
7.2 North America Recombinant Activated Coagulation Factor VII Sales by Application (2017-2028)
7.3 North America Recombinant Activated Coagulation Factor VII Market Size by Country
7.3.1 North America Recombinant Activated Coagulation Factor VII Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Activated Coagulation Factor VII Sales by Type (2017-2028)
8.2 Europe Recombinant Activated Coagulation Factor VII Sales by Application (2017-2028)
8.3 Europe Recombinant Activated Coagulation Factor VII Market Size by Country
8.3.1 Europe Recombinant Activated Coagulation Factor VII Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant Activated Coagulation Factor VII Market Size by Region
9.3.1 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant Activated Coagulation Factor VII Sales by Type (2017-2028)
10.2 South America Recombinant Activated Coagulation Factor VII Sales by Application (2017-2028)
10.3 South America Recombinant Activated Coagulation Factor VII Market Size by Country
10.3.1 South America Recombinant Activated Coagulation Factor VII Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant Activated Coagulation Factor VII Market Size by Country
11.3.1 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant Activated Coagulation Factor VII and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant Activated Coagulation Factor VII
12.3 Recombinant Activated Coagulation Factor VII Production Process
12.4 Recombinant Activated Coagulation Factor VII Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant Activated Coagulation Factor VII Typical Distributors
13.3 Recombinant Activated Coagulation Factor VII Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Recombinant Activated Coagulation Factor VII Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant Activated Coagulation Factor VII Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Recombinant Activated Coagulation Factor VII Product and Services
Table 6. Novo Nordisk Recombinant Activated Coagulation Factor VII Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. LFB SA HEMA Biologics Basic Information, Manufacturing Base and Competitors
Table 8. LFB SA HEMA Biologics Major Business
Table 9. LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Product and Services
Table 10. LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. AryoGen Pharmed Basic Information, Manufacturing Base and Competitors
Table 12. AryoGen Pharmed Major Business
Table 13. AryoGen Pharmed Recombinant Activated Coagulation Factor VII Product and Services
Table 14. AryoGen Pharmed Recombinant Activated Coagulation Factor VII Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Global Recombinant Activated Coagulation Factor VII Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Units)
Table 16. Global Recombinant Activated Coagulation Factor VII Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 17. Market Position of Manufacturers in Recombinant Activated Coagulation Factor VII, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 18. Global Recombinant Activated Coagulation Factor VII Production Capacity by Company, (Units): 2020 VS 2021
Table 19. Head Office and Recombinant Activated Coagulation Factor VII Production Site of Key Manufacturer
Table 20. Recombinant Activated Coagulation Factor VII New Entrant and Capacity Expansion Plans
Table 21. Recombinant Activated Coagulation Factor VII Mergers & Acquisitions in the Past Five Years
Table 22. Global Recombinant Activated Coagulation Factor VII Sales by Region (2017-2022) & (Units)
Table 23. Global Recombinant Activated Coagulation Factor VII Sales by Region (2023-2028) & (Units)
Table 24. Global Recombinant Activated Coagulation Factor VII Revenue by Region (2017-2022) & (USD Million)
Table 25. Global Recombinant Activated Coagulation Factor VII Revenue by Region (2023-2028) & (USD Million)
Table 26. Global Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 27. Global Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 28. Global Recombinant Activated Coagulation Factor VII Revenue by Type (2017-2022) & (USD Million)
Table 29. Global Recombinant Activated Coagulation Factor VII Revenue by Type (2023-2028) & (USD Million)
Table 30. Global Recombinant Activated Coagulation Factor VII Price by Type (2017-2022) & (US$/Unit)
Table 31. Global Recombinant Activated Coagulation Factor VII Price by Type (2023-2028) & (US$/Unit)
Table 32. Global Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 33. Global Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 34. Global Recombinant Activated Coagulation Factor VII Revenue by Application (2017-2022) & (USD Million)
Table 35. Global Recombinant Activated Coagulation Factor VII Revenue by Application (2023-2028) & (USD Million)
Table 36. Global Recombinant Activated Coagulation Factor VII Price by Application (2017-2022) & (US$/Unit)
Table 37. Global Recombinant Activated Coagulation Factor VII Price by Application (2023-2028) & (US$/Unit)
Table 38. North America Recombinant Activated Coagulation Factor VII Sales by Country (2017-2022) & (Units)
Table 39. North America Recombinant Activated Coagulation Factor VII Sales by Country (2023-2028) & (Units)
Table 40. North America Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2022) & (USD Million)
Table 41. North America Recombinant Activated Coagulation Factor VII Revenue by Country (2023-2028) & (USD Million)
Table 42. North America Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 43. North America Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 44. North America Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 45. North America Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 46. Europe Recombinant Activated Coagulation Factor VII Sales by Country (2017-2022) & (Units)
Table 47. Europe Recombinant Activated Coagulation Factor VII Sales by Country (2023-2028) & (Units)
Table 48. Europe Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2022) & (USD Million)
Table 49. Europe Recombinant Activated Coagulation Factor VII Revenue by Country (2023-2028) & (USD Million)
Table 50. Europe Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 51. Europe Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 52. Europe Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 53. Europe Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 54. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Region (2017-2022) & (Units)
Table 55. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Region (2023-2028) & (Units)
Table 56. Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue by Region (2017-2022) & (USD Million)
Table 57. Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue by Region (2023-2028) & (USD Million)
Table 58. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 59. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 60. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 61. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 62. South America Recombinant Activated Coagulation Factor VII Sales by Country (2017-2022) & (Units)
Table 63. South America Recombinant Activated Coagulation Factor VII Sales by Country (2023-2028) & (Units)
Table 64. South America Recombinant Activated Coagulation Factor VII Revenue by Country (2017-2022) & (USD Million)
Table 65. South America Recombinant Activated Coagulation Factor VII Revenue by Country (2023-2028) & (USD Million)
Table 66. South America Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 67. South America Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 68. South America Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 69. South America Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 70. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Region (2017-2022) & (Units)
Table 71. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Region (2023-2028) & (Units)
Table 72. Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue by Region (2017-2022) & (USD Million)
Table 73. Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue by Region (2023-2028) & (USD Million)
Table 74. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Type (2017-2022) & (Units)
Table 75. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Type (2023-2028) & (Units)
Table 76. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Application (2017-2022) & (Units)
Table 77. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Application (2023-2028) & (Units)
Table 78. Recombinant Activated Coagulation Factor VII Raw Material
Table 79. Key Manufacturers of Recombinant Activated Coagulation Factor VII Raw Materials
Table 80. Direct Channel Pros & Cons
Table 81. Indirect Channel Pros & Cons
Table 82. Recombinant Activated Coagulation Factor VII Typical Distributors
Table 83. Recombinant Activated Coagulation Factor VII Typical Customers
List of Figures
Figure 1. Recombinant Activated Coagulation Factor VII Picture
Figure 2. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Type in 2021
Figure 3. Vial
Figure 4. Prefilled Syringe
Figure 5. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Application in 2021
Figure 6. Hemophilia A
Figure 7. Hemophilia B
Figure 8. Other
Figure 9. Global Recombinant Activated Coagulation Factor VII Revenue, (USD Million) & (Units): 2017 & 2021 & 2028
Figure 10. Global Recombinant Activated Coagulation Factor VII Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Recombinant Activated Coagulation Factor VII Sales (2017-2028) & (Units)
Figure 12. Global Recombinant Activated Coagulation Factor VII Price (2017-2028) & (US$/Unit)
Figure 13. Global Recombinant Activated Coagulation Factor VII Production Capacity (2017-2028) & (Units)
Figure 14. Global Recombinant Activated Coagulation Factor VII Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Recombinant Activated Coagulation Factor VII Market Drivers
Figure 16. Recombinant Activated Coagulation Factor VII Market Restraints
Figure 17. Recombinant Activated Coagulation Factor VII Market Trends
Figure 18. Global Recombinant Activated Coagulation Factor VII Sales Market Share by Manufacturer in 2021
Figure 19. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Manufacturer in 2021
Figure 20. Recombinant Activated Coagulation Factor VII Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Recombinant Activated Coagulation Factor VII Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Recombinant Activated Coagulation Factor VII Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Recombinant Activated Coagulation Factor VII Sales Market Share by Region (2017-2028)
Figure 24. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Region (2017-2028)
Figure 25. North America Recombinant Activated Coagulation Factor VII Revenue (2017-2028) & (USD Million)
Figure 26. Europe Recombinant Activated Coagulation Factor VII Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue (2017-2028) & (USD Million)
Figure 28. South America Recombinant Activated Coagulation Factor VII Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue (2017-2028) & (USD Million)
Figure 30. Global Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2017-2028)
Figure 31. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Type (2017-2028)
Figure 32. Global Recombinant Activated Coagulation Factor VII Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 34. Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Application (2017-2028)
Figure 35. Global Recombinant Activated Coagulation Factor VII Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2017-2028)
Figure 37. North America Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 38. North America Recombinant Activated Coagulation Factor VII Sales Market Share by Country (2017-2028)
Figure 39. North America Recombinant Activated Coagulation Factor VII Revenue Market Share by Country (2017-2028)
Figure 40. United States Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2017-2028)
Figure 44. Europe Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 45. Europe Recombinant Activated Coagulation Factor VII Sales Market Share by Country (2017-2028)
Figure 46. Europe Recombinant Activated Coagulation Factor VII Revenue Market Share by Country (2017-2028)
Figure 47. Germany Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Recombinant Activated Coagulation Factor VII Revenue Market Share by Region (2017-2028)
Figure 56. China Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2017-2028)
Figure 63. South America Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 64. South America Recombinant Activated Coagulation Factor VII Sales Market Share by Country (2017-2028)
Figure 65. South America Recombinant Activated Coagulation Factor VII Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Recombinant Activated Coagulation Factor VII Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Recombinant Activated Coagulation Factor VII in 2021
Figure 77. Manufacturing Process Analysis of Recombinant Activated Coagulation Factor VII
Figure 78. Recombinant Activated Coagulation Factor VII Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 組換え活性型凝固第VII因子のグローバル市場展望 2023年-2029年：バイアル、プレフィルドシリンジ
  • 凝固第VIIa因子のグローバル市場展望 2023年-2029年：ノボセブン、ノボセブンRT
  • 世界のフォン・ヴィレブランド因子（組換え）市場2022年：市場規模予測（～2028年）
  • 組換えカスケード試薬（rCR）＆組換えファクターCのグローバル市場展望 2023年-2029年：リコンビナントファクターC、リコンビナントカスケード試薬（rCR）
  • 組換えヒト凝固VIIaの世界市場2023年：プレフィルドシリンジ、バイアル
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19594 )"世界の組換え活性化凝固第VII因子市場2022年：市場規模予測（～2028年）" (英文：Global Recombinant Activated Coagulation Factor VII Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。